Health News Norwegian antigen production consolidated
PHARMAQ has entered into a long-term agree- ment with the Norwegian Institute of Public Health (NIPH) for the lease of virus antigen production facilities in Oslo. This expansion comes on top of current production capacity and will be accompanied by investments of up to NOK 30 million in equipment and expertise development. Production will be carried out by Pharmaq’s own employees as well as contracted person- nel from the NIPH, while the expansion will also create a number of new employment opportunities too, with appli- cations to be invited shortly. Organisation in the new premises will be completed by the end of the year, while initial production of virus antigen from the new unit is expected early in 2012. This
new organisation will repre- sent a considerable consolida- tion of Norwegian expertise in the fi eld of virus antigen production.
Forwards
‘The establishment of pro- duction in Oslo represents an important step forward for us’, says Managing Director Morten Nordstad. ‘Develop- ments in recent years have demonstrated that a vari- ety of virus components are incorporated in an increasing number of different vaccines. In 2010 alone we supplied almost 300 million vaccine doses containing different virus antigens. It is vital to us to consolidate our production capacity – both for existing virus antigens and for those which will be developed in the future. We also see it as important to develop fl exible
production approaches which will enable us to meet poten- tial situations demanding rapid increases in production, such as acute disease epidem- ics within the aquaculture industry.
‘Developments in the use of viral vaccines in the global aquaculture industry are ac- celerating rapidly, accompa- nied by a great need for new vaccines for new species. A production unit at the NIPH – with close links Pharmaq’s R&D facilities, which are also located in Oslo – will contrib- ute to a more rapid develop- ment of new virus antigens from the R&D stage to full production. Overall, this investment will strengthen our value chain and promote the development of new and effective quality products from Pharmaq’, Nordstad concludes.
Morten Nordstad: Pharmaq’s MD
Don’t go to sea
without it!
Compact PD aids in the protection against PD. It helps reduce mortalities, virus replication and lesions of pancreas disease caused by salmonid alphavirus (SAV). – Ask your vet about Norvax®
Norvax® Compact PD today! Norvax
Norvax® Norvax®
Compact PD contains inactivated Salmonid alphavirus (SAV). POM-V. Additional information and advice is available from your veterinary surgeon. is a trademark of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property
www.fishfarmer-magazine.com
laws. Copyright © 2011 Intervet International B.V., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. Further information can be obtained from MSD Animal Health, Walton Manor, Milton Keynes MK7 9AJ. Tel: 03700 603380.
11 Fish Farmer September/October 2011
® COMPACT PD
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52